Temozolomide

Category API

Details	Specifications
CAS Number	85622-93-1
Molecular Formula	C6H6N6O2
Molecular Weight	194.15 g/mol.
Synonyms	3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d] [1,2,3,5] tetrazine-8-carboxamide
Chemical Name	3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5- tetrazine-8-carboxamide
Common name	Temozolomide
Therapeutic use	Temozolomide is an alkylating agent used to treat glioblastoma multiforme and refractory anaplastic astrocytoma.
Background	Temozolomide was first licensed in 1999, initially as second-line therapy for glioblastoma (GBM), the most malignant grade of glioma, because it was the first alkylating agent that showed a clear improvement in two-year survival rates, from 10% to 25% in glioma patients, and four- and five-year survival rates.
Grade	EP and USP
Polymorph	Form-IA
GTI	Risk assessment report available
Nitrosamines	Risk assessment report available
DMF Availability	USDMF# 23479, CEP 2016 -277 - Rev 00
Manufacturing batch size	20.0 kg
Production capacity	Annual capacity 2.0 - 2.2 tonnes
Stability data	Available

Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*

Disclaimer:

The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.

Why Shilpa Pharma?

Happy Customers

Projects Successfully Completed

Established

PhD Experts Driving R&D Excellence

Team Size

World-Class API Manufacturing Sites

Global Audits Successfully Completed

Comprehensive CDMO Service Offerings

Our Temozolomide are also Available for

Questions & Answers

FAQ on Temozolomide

Everything You Need to Know About Shilpa Pharma

Shilpa Pharma – Your Trusted Global CDMO Partner

Delivering end-to-end solutions across API oncology, generics, peptides, polymers and specialty chemicals, we empower partners to accelerate development, ensure compliance, and reach markets faster with reliable, cost-effective innovation.